



CanVECTOR Member Abstracts & Presentations

ASH Annual Meeting and Exposition
December 10-13, 2022

[Saturday](#) | [Sunday](#) | [Monday](#)

Day / Time / Session	Title	Presenter / Author
Saturday, December 10		
<ul style="list-style-type: none"> • 5:30 PM-7:30 PM • Room: Hall D • Program: Oral and Poster Abstracts • Session: 301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Poster I 	1124 Investigating ITP Plasma for Effect on Platelet Production Using the Autologous Peripheral Blood Based Megakaryopoiesis Assay	Nikola Ivetic, BSc and Ishac Nazy, PhD
<ul style="list-style-type: none"> • 5:30 PM-7:30 PM • Room: Hall D • Program: Oral and Poster Abstracts • Session: 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster I 	1137 First-in-Human Detection of Romiplostim Drug Levels in Cord Blood, Breastmilk and Blood in a Woman with ITP and Her Newborn Infant	Steven Roy, MD, Audrey Ann Labrecque, MD, Antoine Dufour, Laurent Brechenmacher, Daniel Young, Si An Chen, Doan Le, MD, Stephanie Cooper, MD, Paul Gibson, MD, Ann E. Clarke, MD and Leslie Skeith, MD

<ul style="list-style-type: none"> • 5:30 PM-7:30 PM • Room: Hall D • Program: Oral and Poster Abstracts • Session: 331. Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-related Thrombotic/Vascular Disorders: Clinical and Epidemiological: Poster I 	1175 Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL	Marc Carrier, MD, MSc
<ul style="list-style-type: none"> • 5:30 PM-7:30 PM • Room: Hall D • Program: Oral and Poster Abstracts • Session: 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster I 	1184 Thrombophilia Gene Mutations for the Prediction of Venous Thromboembolism in Ambulatory Cancer Patients Receiving Chemotherapy	<u>Danielle Carole Roy, BSc</u> , Tzu-Fei Wang, MD, MPH , Ranjeeta Mallick, PhD, MSc, BSc, Philip S. Wells, MD, MSc, FRCPC , Marc Carrier, MD, MSc, FRCPC and Steven Hawken, PhD, MSc, BSc
	1187 Anticoagulation and/or Antiplatelet in Thrombotic Antiphospholipid Syndrome with Previous Arterial Thromboembolism: A Retrospective Cohort	<u>Norah Alnegheimish, MBBS</u> , Eric Kaplovitch, MD, Rita Selby, MBBS, FRCPC and Jameel Abdulrehman, MD, FRCP
Sunday, December 11		
<ul style="list-style-type: none"> • 10:30 AM • Room: 295-296 • Program: Oral and Poster Abstracts • Type: Oral • Session: 904. Outcomes Research—Non-Malignant Conditions: Classical Hematology: From Horses to Zebras 	509 Risk of Venous Thromboembolism or Hemorrhage Among Individuals with Chronic Kidney Disease Taking a Direct Oral Anticoagulant Compared to Low-Molecular-Weight Heparin after a Hip or Knee Arthroplasty	Tzu-Fei Wang, MD, MPH , Nicolas Grubic, Peter Tanuseputro, MD and Manish Sood, MD, MSc, FRCPC

<ul style="list-style-type: none"> • 12:00 PM • Room: 291-292 • Program: Oral and Poster Abstracts • Type: Oral • Session: 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Cancer-associated Thrombosis: Risk Stratification, Prevention, and Treatment • 1:15 PM 	517 A Prospective Study of Apixaban for Central Venous Catheter Associated Upper Extremity Deep Vein Thrombosis in Cancer Patients: Catheter 3	Michael J. Kovacs, MD, Philip S. Wells, MD, MSc, FRCPC, Marc A. Rodger, MD, MSc, Marc Carrier, MD, MSc, FRCPC, Erik Yeo, MD, FACP, FRCPC, Judy A Kovacs, RN and Alejandro Lazo-Langner, MD, MSc, FRCPC
	522 Rivaroxaban Versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism: A Head-to-Head Analysis of the United States Cohort of the Observational Study in Cancer-Associated Thrombosis for Rivaroxaban: (H2H-OSCAR-US)	Kimberly Snow Caroti, PharmD, Khaled Abdelgawwad, MSc, MBA, George Psaroudakis, PhD, Marcela Rivera, PhD, Gunnar Brobert, PhD, Alexander T Cohen, MBBS MSc MD FRACP FESC, Alok A Khorana, MD, Cecilia Becattini, MD, Agnes Y. Lee, MD, MSc , Anders Ekblom, MB, MD, PhD, Marc Carrier, MD, MSc and Craig I. Coleman, PharmD
<ul style="list-style-type: none"> • 4:30 PM-6:00 PM • Room: 271-273 • Program: Special-Interest Sessions • Session: ASH Guidelines on VTE: Prevention and Treatment in Patients with Cancer 	Risk Assessment and Prophylaxis	Marc Carrier, MD, MSc, FRCPC
<ul style="list-style-type: none"> • 6:00 PM-8:00 PM • Room: Hall D • Program: Oral and Poster Abstracts • Session: 322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster II 	2487 Derivation and External Validation of Clinical Risk Assessment Model for Cancer Associated Thrombosis in Two Unique U.S. Healthcare Systems Clinically Relevant Abstract	Ang Li, MD, MS, Jennifer La, PhD, Sarah B May, MS, MPH, Danielle Guffey, Wilson L Da Costa Jr., MD MPH PhD, Christopher I Amos, Emily Milner, Raka Bandyo, Carolina Granada, Nimrah Riaz, MS, Nhan V Do, MD, Mary Brophy, MD, MPH, Vipul Chitalia, MD, J. Michael Gaziano, MD, MPH, David A. Garcia, MD, Marc Carrier, MD, MSc, Christopher R.

		Flowers, MD, Neil Zakai, MD and Nathanael Fillmore
<ul style="list-style-type: none"> • 6:00 PM-8:00 PM • Room: Hall D • Program: Oral and Poster Abstracts • Session: 331. Thrombotic Microangiopathies/Thrombocytopenias and COVID-19-related Thrombotic/Vascular Disorders: Clinical and Epidemiological: Poster II 	2488 Longitudinal Characteristics of Anti-Platelet Factor 4 Immunoglobulin G in Vaccine-Induced Immune Thrombotic Thrombocytopenia	Angela Huynh, PhD , Donald M. Arnold, MD, James W. Smith, Rumi Clare, BSc, Nikola Ivetic, BSc, Jane C. Moore, BSc, MT, John G. Kelton, MD and Ishac Nazy, PhD
<ul style="list-style-type: none"> • 6:00 PM-8:00 PM • Room: Hall D • Program: Oral and Poster Abstracts • Session: 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster II 	2509 The Risk of Bleeding in Pregnant Women with Acute Venous Thromboembolism Treated with Anticoagulants	Camille Simard, MD, Isabelle Malhamé, MD, MSc, FRCPC, Antonios Douros, MD, PhD , Kristian B. Filion, PhD, Haim Abenhaim, MD, MPH, FRCSC and Vicky Tagalakis, MD, FRCPC
	2510 Comparative Analysis of 4 Risk Stratification Models to Identify Patients with Acute Pulmonary Embolism at Risk of Short Term Mortality in a Canadian Health Region	Kwadwo Osei Bonsu, PharmD , Stephanie W Young, PharmD , Tiffany Lee, BSc(Pharm), Pharm.D, Rufaro S Chitsike, MBChB, MMed(Haem) , FCPATH(Haem), Cert Clin(Haem) and Hai V Nguyen, PhD
	2514 Trends in Drug Treatment of Outpatients with Acute Pulmonary Embolism - a 5-Year Retrospective Cohort Study in One Canadian Health Region	Stephanie W Young, PharmD , Michael Coombs, Pharmacy Student, Kwadwo Osei Bonsu, PharmD, Tiffany Lee, BSc(Pharm), Pharm.D, Hai V Nguyen, PhD and Rufaro S Chitsike, MBChB, MMed(Haem), FCPATH(Haem), Cert Clin(Haem)

	2517 Blood Biomarkers for the Prediction of Venous Thromboembolism in Perioperative or Hospitalized Cancer Patients: A Systematic Review	<u>Danielle Carole Roy</u> , BSc, Amin Zahrai, MSc , Ronda Lun, MD, Tzu-Fei Wang, MD , MPH, Steven Hawken, PhD, MSc, BSc, Ranjeeta Mallick, PhD, MSc, BSc, Dylan Burger, PhD and Philip S. Wells, MD, MSc, FRCPC
<ul style="list-style-type: none"> • 6:00 PM-8:00 PM • Room: Hall D • Program: Oral and Poster Abstracts • Session: 901. Health Services and Quality—Non-Malignant Conditions: Poster II 	3503 Clinical Benefits, Harms, and Cost-Effectiveness of Indefinite Anticoagulant Therapy for First Unprovoked Venous Thromboembolism: A Decision Analytic Modelling Study	Faizan Khan, MSc , Doug Coyle, MA, MSc, PhD, Kednapa Thavorn, MPharm, PhD, Sasha van Katwyk, MSc, Tobias Tritschler, MD , Brian Hutton, PhD, Gregoire Le Gal, MD, PhD, Marc A. Rodger, MD, MSc and Dean Fergusson, PhD
	3519 Inferior Vena Cava Filter Use at a Large Community Hospital: A Cross-Sectional Analysis	Kaity Greco, Samantha Bolger, Yuxin Bai, Stephanie Fontyn, Caroline Hamm, MD and Andrea Cervi, MD
<ul style="list-style-type: none"> • 6:00 PM-8:00 PM • Room: Hall D • Program: Oral and Poster Abstracts • Session: 903. Health Services and Quality—Myeloid Malignancies: Poster II 	3546 Clinical Features and Mutational Landscape of Patients Referred for Suspected Essential Thrombocytosis: A Descriptive Study Using a ‘Real-World’ Database	<u>Ala Almanaseer</u> , BSc, Benjamin Chin-Yee, MD, FRCPC, MA, Pratibha Bhai, PhD, Ian Cheong, BMSc, Alejandro Lazo-Langner, MD, MSc , FRCPC, Jenny M. Ho, MD, Michael A. Levy, PhD, Alan Stuart, BSc, MLT, Hanxin Lin, PhD, Ian Chin-Yee, MD, FRCPC, Bekim Sadikovic, PhD, DABMGG, FACMG and Cyrus C. Hsia, MD, BSc, FRCPC
<ul style="list-style-type: none"> • 6:00 PM-8:00 PM • Room: Hall D • Program: Oral and Poster Abstracts • Session: 904. Outcomes Research—Non-Malignant Conditions: Poster II 	3555 Venous Thromboembolism Risk in Cancer Patients Receiving First-Line Immune Checkpoint Inhibitor Vs. Chemotherapy Clinically Relevant Abstract	<u>Sarah B May</u> , MS, MPH, Jennifer La, PhD, Emily Milner, Nimrah Riaz, MS, Christopher I Amos, David A. Garcia, MD, Marc Carrier, MD, MSc , Neil Zakai, MD, Nhan V Do, MD, Mary Brophy, MD, MPH, Vipul Chitalia, MD, J. Michael

		Gaziano, MD, MPH, Nathanael Fillmore and Ang Li, MD, MS
Monday, December 12		
<ul style="list-style-type: none"> • 2:45 PM-4:00 PM • Room: 288-290 • Program: Spotlight Sessions • Session: Education Spotlight 	Point/Counterpoint: The case for/against thrombophilia testing in many/most adults with unprovoked thrombosis.	Deborah M. Siegal, MD
<ul style="list-style-type: none"> • 4:30 PM-5:45 PM • Room: R02-R05 • Program: Education Program • Session: Thrombosis Prevention and Treatment 	Frequently Asked Questions about Factor Xa Inhibitors	Tzu-Fei Wang, MD, MPH
<ul style="list-style-type: none"> • 6:00 PM-8:00 PM • Room: Hall D • Program: Oral and Poster Abstracts • Session: 301. Vasculature, Endothelium, Thrombosis and Platelets: Basic and Translational: Poster III 	3752 Evaluating Doac Efficacy and Safety Against Vka/LMWH in Patients with Atrial Fibrillation and Malignancies: A Systemic Review and Meta-Analysis	Ciuffini Leonardo Augusto, Aurelien Delluc, MD, PhD, Tzu-Fei Wang, MD, MPH, Corrado Lodigiani, MD, PhD and Marc Carrier, MD, MSc
<ul style="list-style-type: none"> • 6:00 PM-8:00 PM • Room: Hall D • Program: Oral and Poster Abstracts • Session: 322. Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster III 	3796 Real-World Outcomes of Emicizumab in Hemophilia A with or without FVIII Inhibitors from the Canadian Hemophilia Bleeding Disorder Registry	Man-Chiu Poon, MD, Adrienne Lee, MD, Federico Germini, MD , Arun Keepanasseril, MDS, Quazi Ibrahim, MSc, Francis Nissen, MD, PhD, Katya Moreno, MD, Michelle Santos, MN, NP, Emma Iserman, BA, Davide Matino, MD and Alfonso Iorio, MD

<ul style="list-style-type: none"> • 6:00 PM-8:00 PM • Room: Hall D • Program: Oral and Poster Abstracts • Session: 332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster III 	3822 Predictors of 90-Day Mortality in Patients with Acute Pulmonary Embolism— a 5-Year Retrospective Cohort Study of Patients in One Canadian Health Region	<p>Kwadwo Osei Bonsu, PharmD, Stephanie W Young, PharmD, Tiffany Lee, BSc(Pharm), Pharm.D, Hai V Nguyen, PhD and Rufaro S Chitsike, MBChB, MMed(Haem), FCPATH(Haem), Cert Clin(Haem)</p>
	3823 Performance of D-Dimers in Patients with Prior History of Venous Thromboembolism Based on Anticoagulation Status	<p>Vicky Mai, MD, Emily S.L. Martens, M, Marc Righini, M, Sam Schulman, MD, PhD, FRCPC, Venkatesh Thiruganasambandamoorthy, MD, Susan Kahn, MD, Veronica Bates, BSc, Amanda Pecarskie, BSc, Michael J. Kovacs, MD, Shaun Visser, M, Sudeep P Shivakumar, MD, BS, Melanie Tan, M, Marc A. Rodger, MD, MSc, Dimitrios Scarvelis, MD, Aurelien Delluc, MD, PhD, Philippe Girard, M, Menno V Huisman, MD PhD FESC, Philip S. Wells, MD, MSc, FRCPC, Frederikus A Klok, MD, PhD and Gregoire Le Gal, MD, PhD</p>
	3827 The Safety and Efficacy of Anticoagulation for the Management of Isolated Distal Deep Vein Thrombosis in Patients with Cancer	<p>Cameron Brown, Willem Brandt, Tzu-Fei Wang, MD, MPH, Aurelien Delluc and Marc Carrier, MD, MSc</p>
	3830 Management of Anticoagulation and Related Outcomes in Patients with Cancer-Associated Thrombosis and Thrombocytopenia: A Systematic Review and Meta-Analysis	<p>Tzu-Fei Wang, MD, MPH, Aurelien Delluc, MD, PhD, Marc Carrier, MD, MSc and Miriam Kimpton, MD</p>